查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球动物疫苗市场 - 2023-2030年
市场调查报告书
商品编码
1285061

全球动物疫苗市场 - 2023-2030年

Global Animal Vaccine Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球动物疫苗市场在2022年达到120.892亿美元，预计到2030年将出现有利可图的增长，达到224.043亿美元。在预测期内（2023-2030），全球动物疫苗市场预计将呈现8.2%的复合增长率。

疫苗接种对于保护动物健康和福祉至关重要。长期以来，它已被证明是降低农场和家庭动物疾病负担的有效方法。动物健康和疾病预防计划继续越来越多地依赖于疫苗接种。

全球动物疫苗市场正在扩大，因为包括不断增加的研究和开发及其即将在各国获得的医疗批准等因素，也为动物疫苗市场的增长创造了一个积极的前景。越来越多的动物采用和新型疫苗的临床试验不断增加，也推动了动物疫苗市场的需求趋势。

市场动态

不断增长的研究和开发推动了动物疫苗市场的增长

在动物疫苗领域正在进行各种新颖的研究和开发。研究人员在欧盟的资助下创造的新牲畜疫苗有可能最大限度地减少抗生素耐药性，提高动物福利，节省资金，并减少对危害环境的化学品的需求。欧盟资助的SAPHIR项目努力通过创造新鲜、有效的疫苗来解决动物疾病预防方面的差距。

研究人员重点关注那些造成重大经济损失和对抗生素治疗有强烈需求的疾病。来自SAPHIR的研究人员利用最新的基因组学和生物统计学方法，确定了建立包含对疫苗高反应的育种技术的生物标志物。

此外，他们还使用数学建模技术来预测疫苗在实践中的效果如何。他们利用尖端技术创造了候选疫苗，可以对最近发现的疾病菌株提供广泛的免疫力。该团队在项目结束时已经为影响猪、鸡和牛的六种重要牲畜传染病生产了动物疫苗候选物。因此，不断增长的研究正在推动动物疫苗的市场规模。

政府倡议的增加和新产品的推出为制造商创造了有利可图的机会

由于不断进步和监管部门的批准，以及传染病的日益流行，动物疫苗市场机会越来越多。主要的关键参与者推出的新产品不断增加，也推动了市场的发展。

许多政府和非政府组织都采取了行动，如欧盟-日本-美国三边计划的《兽药注册技术标准协调国际合作》（VICH），其目的是协调兽药产品注册的技术规范。

VICH的责任是规范兽药产品上市许可所需信息的技术标准。这是通过为营销许可申请中必须包含的研究制定统一的标准来实现的。

动物健康意识的缺乏将阻碍市场的发展

动物健康是至关重要的，因为不健康的动物会产生广泛的负面效应。此外，影响人类的动物疾病会对其他经济部门产生影响，如全球贸易、农业稳定和公共卫生。因此，上述因素将在预测期内限制动物健康市场的增长。

COVID-19影响分析

世界上许多国家的COVID-19大流行和封锁，影响了所有行业的公司的财务健康。因此，在COVID-19公共卫生紧急情况期间，美国食品和药物管理局（FDA）发布了指导方针，其中包括帮助赞助商和研究人员的一般考虑，确保试验参与者的安全，坚持良好的临床实践（GCP），并尽量减少对动物试验完整性的风险。

俄乌战争影响分析

俄罗斯-乌克兰冲突估计对全球动物疫苗市场的影响不大，因为该地区的主要市场参与者数量较少。然而，在预测期内，原材料进出口的影响预计对全球动物疫苗市场的增长影响不大。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品类型分析
  • 按动物类型简述
  • 按给药途径分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 动物疫苗生产的不断创新
      • 研究与开发的不断发展
    • 限制因素
      • 缺乏动物健康意识
    • 机会
      • 监管部门的批准和新产品的推出不断增加
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19及未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按产品类型

  • 改良的活疫苗（减毒疫苗
  • 灭活（杀灭）疫苗
  • 重组疫苗
  • 类毒素疫苗

第8章：按动物类型分类

  • 伴侣动物
    • 猫科动物
    • 犬类
    • 其他动物
  • 畜牧业动物
    • 家禽
    • 猪
    • 牛
    • 其他
  • 水产养殖

第9章：按给药途径

  • 皮下注射
  • 肌内注射
  • 鼻内注射

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 关键区域的动态

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Merck & Co., Inc.
    • 公司概述
    • 产品组合和说明
    • 财务概况
    • 主要发展情况
  • Boehringer Ingelheim International GmbH
  • Zoetis Services LLC
  • Ceva
  • Vetoquinol
  • Elanco
  • Veterquimica S.A.
  • Phibro Animal Health Corporation
  • KBNP, Inc.
  • Kyoto Biken Laboratories, Inc.

第十三章 ：附录

简介目录
Product Code: VH6437

Market Overview

The global animal vaccine market reached US$ 12,089.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 22,404.3 million by 2030. The global animal vaccine market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).

Vaccination is vital in preserving animal health and well-being. It has long been proven to be an effective method of lowering disease burden in farm and domestic animals. Animal health and illness prevention programs continue to depend more and more on vaccinations.

The global market for animal vaccines is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the animal vaccine market growth. The increasing adoption of animals and the growing clinical trials for novel vaccines are also driving up demand for animal vaccine market trends.

Market Dynamics

The Rising Research and Development Drive the Growth of the Animal Vaccine Market

Various novel research and developments are being done in the field of animal vaccines. New livestock vaccinations created by researchers with funding from the EU have the potential to minimize antibiotic resistance, increase animal welfare, save money, and lessen the need for chemicals that harm the environment. The EU-funded SAPHIR project made an effort to address the gaps in animal illness prevention by creating fresh, potent vaccinations.

The researchers focused on conditions that cause significant economic losses and a strong demand for antibiotic treatments. Researchers from SAPHIR have identified biomarkers for establishing breeding techniques that incorporate high response to vaccines using the most recent genomic and biostatistical approaches.

In addition, they have used mathematical modeling techniques to forecast how well vaccines will work in practice. They have created vaccination candidates using cutting-edge technologies that can offer wide immunity against recently discovered disease strains. The team has produced animal vaccine candidates for six important livestock infections that impact pigs, chickens, and cattle at the project's conclusion. Hence, the growing research is driving the animal vaccine market size.

Rising Government Initiatives and Novel Product Launches Creates Lucrative Opportunities for Manufacturers

There is a growing animal vaccine market opportunity owing to rising advancements and regulatory approvals and the increasing prevalence of infectious diseases. The rising novel product launches by major key players is also driving the market.

Actions are taken by numerous governmental and non-governmental organizations, such as the trilateral European Union-Japan-US program International Cooperation on Harmonization of Technical Standards for Registration of Veterinary Medicinal Products (VICH), which aims to harmonize the technical specifications for veterinary product registration.

VICH's responsibility is to standardize the technical standards for the information required for a veterinary medical product's marketing authorization. This is accomplished by creating unified standards for the research that must be included in a marketing permission application.

A Lack of Animal Health Awareness will Hamper the Growth of the Market

Animal health is crucial because unhealthy animals can have a wide range of negative effects. Additionally, animal diseases that affect humans can have an effect on other economic sectors such as global trade, agricultural stability, and public health. Hence, the above-mentioned factors will be limiting the animal health market growth over the forecast period.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity for animals.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global animal vaccine market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global animal vaccine market growth over the forecast period.

Segment Analysis

The global animal vaccine market is segmented based on product type, animal type, route of administration and region.

Inactivated Vaccines From Product Type Segment Account for 40.3% of the Market Share Owing to Rising Novel Product Launches

In 2022, the inactivated vaccines segment held a dominant position in the global animal vaccine market. The segment is advantageous because inactivated vaccinations, also known as killed vaccines, are made by killing a pathogen that has been grown and then turned into a vaccine. These vaccines are often used to protect against a variety of bacterial and viral illnesses.

Furthermore, inactivated vaccines elicit powerful immune responses by retaining the inactive genetic element, and the virus surface antigens are essential for a powerful immunological response. Additionally, inactivated immunization is safe and has a higher demand because it doesn't remain in the surroundings or in the fish who have received it.

As a result, there is now a greater need for inactivated aquaculture vaccinations. The market segment is predicted to have the greatest market share during the projection period based on the aforementioned assertions.

Geographical Analysis

North America Accounted For Approximately 39.8% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for animal vaccines for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of animal vaccines, which has increased the demand. North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for animal vaccines.

Rising new drug or infection types will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals, and novel product launches. Researchers are becoming more aware of various kinds of treatment or prevention approaches for infectious disorders, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the animal vaccine market include: Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Services LLC, Ceva, Vetoquinol, Elanco, Veterquimica S.A., Phibro Animal Health Corporation, KBNP, Inc. and Kyoto Biken Laboratories, Inc. among others.

Why Purchase the Report?

  • To visualize the global animal vaccine market segmentation based on product type, animal type, route of administration and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of animal vaccine market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global animal vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Animal Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Innovation in Animal Vaccine Production
      • 4.1.1.2. The Rising Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Animal Health Awareness
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Regulatory Approvals and Novel Product Launches
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Modified-live (attenuated) Vaccine *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Inactivated (killed) Vaccine
  • 7.4. Recombinant Vaccine
  • 7.5. Toxoid Vaccine

8. By Animal Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
    • 8.1.2. Market Attractiveness Index, By Animal Type
  • 8.2. Companion Animal *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Feline
    • 8.2.4. Canine
    • 8.2.5. Others
  • 8.3. Livestock Animal
    • 8.3.1. Poultry
    • 8.3.2. Swine
    • 8.3.3. Cattle
    • 8.3.4. Others
  • 8.4. Aquaculture

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Subcutaneous *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Intramuscular
  • 9.4. Intranasal

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co., Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Boehringer Ingelheim International GmbH
  • 12.3. Zoetis Services LLC
  • 12.4. Ceva
  • 12.5. Vetoquinol
  • 12.6. Elanco
  • 12.7. Veterquimica S.A.
  • 12.8. Phibro Animal Health Corporation
  • 12.9. KBNP, Inc.
  • 12.10. Kyoto Biken Laboratories, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us